Brief: Nordic Nanovector: Results From Preclinical Studies With Novel Cd37-Targeted Alpha Therapy

Thor Medical ASA

02/04/2019 06:26

April 2 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * NORDIC NANOVECTOR: PROMISING RESULTS FROM PRECLINICAL
STUDIES
WITH A NOVEL CD37-TARGETED ALPHA THERAPY FOR B-CELL TUMOURS
PRESENTED AT TAT11
    * IN STUDIES, 212PB-NNV003 DISPLAYED A FAVOURABLE TOXICITY
PROFILE
AFTER A SINGLE INTRAVENOUS INJECTION
    * IN ONE STUDY, 100% OF MICE WITH TUMOUR XENOGRAFTS WERE
ALIVE
FIVE MONTHS AFTER INJECTION OF 212PB-NNV003

Source text for Eikon:  ID:nWkr28Mbb9 
Further company coverage:  NANOV.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))